Spyre Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Stocks rose slightly on mixed US economic news. Crude oil prices fell over 8% this week on easing Middle East tensions. S&P 500 Q2 earnings growth is tracking at 32%, driven by AI spending. Summit Therapeutics (SMMT) and Semtech (SMTC) gained over 8% on positive earnings. Kohl's (KSS) and Intuit (INTU) fell over 4% on weak forecasts.
Guggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.
Spyre Therapeutics (SYRE) reported mixed Phase II SKYWAY-RA study results for SPY072 in rheumatoid arthritis. While the low dose met the primary endpoint, the high dose did not. The company will shift focus to broader autoimmune indications and combination therapies. SYRE shares fell 4% in after-hours trading.
Over the past 7 days, alphai's AI scored 7 news stories mentioning SYRE (Spyre Therapeutics, Inc.). Coverage has skewed bearish: 1 bullish, 1 neutral, and 5 bearish.
Recent SYRE coverage spans technology, earnings and insider activity.
In the last 30 days, SYRE insiders filed 11 SEC Form 4 transactions — no purchases and 11 sales ($4.6M). The most active reporter was Turtle Cameron, Chief Executive Officer, with 5 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Negative trial news drags stock lower.
Positive trial data may boost the stock, but program termination could weigh on near-term sentiment.
The mixed trial results and strategic shift likely pressure SYRE stock lower in the short term.
The disappointing RA data triggered a sharp sell‑off, suggesting further downside risk until upcoming readouts.
Positive Phase 2 data may boost near‑term demand while the missed monotherapy target could temper upside.
alphai scores every news story that mentions SYRE with an AI model for sentiment and relevance, and aggregates insider trades from Spyre Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stocks rose slightly on mixed US economic news. Crude oil prices fell over 8% this week on easing Middle East tensions. S&P 500 Q2 earnings growth is tracking at 32%, driven by AI spending. Summit Therapeutics (SMMT) and Semtech (SMTC) gained over 8% on positive earnings. Kohl's (KSS) and Intuit (INTU) fell over 4% on weak forecasts.
3 min readGuggenheim maintains a buy rating on Spyre Therapeutics, citing positive Phase II SKYWAY-RA results for SPY072, despite discontinuing the rheumatoid arthritis program. The firm projects the stock to settle in the $90-95 range, with valuation based on the inflammatory bowel disease program. Other analysts have mixed views, with Wolfe Research downgrading and Mizuho raising its price target to $120.
2 min readSpyre Therapeutics (SYRE) reported mixed Phase II SKYWAY-RA study results for SPY072 in rheumatoid arthritis. While the low dose met the primary endpoint, the high dose did not. The company will shift focus to broader autoimmune indications and combination therapies. SYRE shares fell 4% in after-hours trading.
2 min readSpyre Therapeutics (SYRE) stock fell 11.7% in pre-market trading after Phase 2 trial data for SPY072 in rheumatoid arthritis showed statistically significant but insufficient efficacy to advance as a monotherapy. Wedbush maintained an Outperform rating with a $130 target. The company plans further readouts in 2026 for other indications. The decline is attributed to the clinical news, not broader market trends.
2 min readSpyre Therapeutics (SYRE) reported mixed Phase 2 results for SPY072 in rheumatoid arthritis, showing efficacy but not meeting monotherapy targets. Both doses showed statistically significant benefits over placebo on some endpoints. The company plans to release data on other trials in 2026-2028. Wedbush maintains an outperform rating with a $130 price target. SYRE shares are down 4.06% in overnight trading.
2 min readIntuit forecasted slower sales growth and shares fell 9.8% after-hours. Spyre Therapeutics abandoned a drug candidate after trial results missed targets, dropping 11%. Zoom Communications' Q3 EPS guidance missed estimates, shares down 3.9%. nCino's Q3 revenue projection fell short of expectations, stock down 5.6%.
2 min readIntuit (INTU) fell 9% after lowering FY2027 guidance, missing EPS and revenue estimates. Semtech (SMTC) rose 3% on strong Q2 results and raised Q3 outlook. Spyre Therapeutics (SYRE) dropped 16% due to failed clinical trial results. Zoom (ZM) declined 3.5% despite Q2 beat, citing growth normalization. nCino (NCNO) fell 10% on near-term guidance concerns.
2 min readSpyre Therapeutics (SYRE) shares dropped 14% after-hours. The company reported Phase 2 trial results for SPY072 in rheumatoid arthritis, showing statistically significant benefits over placebo but not meeting internal thresholds for monotherapy development. The trial enrolled 143 participants. The company plans to release further data in 2026 and 2027-2028 for other indications.
2 min readAlbers Jeffrey W. sold 18,000 indirectly-held shares of Spyre Therapeutics, Inc. (SYRE) at an average of $104.55 ($104.38–$104.68, $1.88M total) across 2 trades on 2026-08-07 under a Rule 10b5-1 trading plan.
2 min readAlbers Jeffrey W. sold 5,000 shares of Spyre Therapeutics, Inc. (SYRE) at $104.47 ($0.52M total) on 2026-08-07 under a Rule 10b5-1 trading plan.
2 min read
